Advanced rare disease drug developers are companies or organizations that specialize in the research and development of treatments for rare diseases. Developing drugs for rare diseases poses unique challenges due to small patient populations, genetic variations, and the need for novel endpoint selection. In response, the FDA has allocated resources through initiatives like Prescription Drug […]
Empowering Rare Disease Drug Developers Read More »
In the development of the UK’s medical device industry, a consortium of Approved Bodies (AB) united under the banner of the UK Association for Medical Device Approved Bodies, or simply, Team-AB. This coalition marks a landmark as these bodies converge to advocate for cohesive regulations in the evolving landscape of medical device oversight. The genesis
How is Team AB Gearing up for the new MedTech Legislation? Read More »
In the emerging boom of biopharmaceuticals, the remarkable advancements in cell and gene therapy (CGT) have ushered in a new era of medical possibilities. These groundbreaking treatments have the potential to revolutionize medicine, offering hope to patients with previously untreatable conditions. However, with innovation comes the need for strong regulatory frameworks to ensure safety, efficacy,
Harmonization for the Development of Cell and Gene Therapies Read More »
With the expansion of clinical research and development, precise labeling of investigational products is not merely a formality but a critical aspect ensuring the safety, efficacy, and regulatory compliance of clinical trials. Pharmaceutical companies are obliged to follow an integrated approach in labeling considering all aspects of clinical study planning to promote multilingual and multicultural
Essential Aspects of Labeling for Clinical Supplies and Investigational Products Read More »
The onset of the coronavirus, or COVID-19, created havoc across the globe since its emergence in December 2019 in Wuhan, China, and fast spreading potential. Though no longer considered a “public health emergency” (under section 319 of the Public Health Services Act), the virus and its new strains are still actively circulating. This requires rigorous
Assessing COVID-19 Symptoms in Clinical Trials Read More »
In the realm of healthcare, patients have a fundamental right to transparency and information regarding the procedures they undergo particularly with respect to medical devices used for surgical procedures. One often overlooks the aspect of this right which is the traceability labels for medical devices used in surgical procedures regardless of whether the device is
Asserting Patient Rights: The Importance of Labels for Medical Device Traceability Read More »
Regulatory scrutiny for abbreviated new drug applications (ANDAs) places a strong focus on the accuracy and completeness of ANDA labels. Not only does this provide comprehensive information to healthcare professionals, but it also communicates information on medication usage and potential risks to ensure patients get clear and detailed information. This meticulous review process highlights the
Submitting Revised ANDA Labels to Ensure Safety & Compliance Read More »
Chimeric antigen receptor (CAR) T cell products refer to therapeutic human gene therapy products. They involve the genetic modification of T cell specificity which allows them to recognize a specific target antigen for therapeutic use. CAR T cells are associated with many challenges related to their development, manufacturing, testing, and even clinical evaluation. Therefore, it
Development of CAR T Cell Products Read More »
Timely patient access to affordable treatment options is the goal of healthcare and regulatory agencies worldwide. To support this, early and frequent communication between drug applicants and regulatory agencies is required to expedite generic drug development and approval. Streamlined communication allows a better and clearer understanding of regulatory expectations and facilitates a more efficient application
Model-Integrated Evidence Program for Generic Drugs Read More »
Product-specific bioequivalence guidelines are crucial to support the development of safe, efficacious, and high-quality generic products. They provide information to manufacturers on how they can demonstrate therapeutic equivalence of their products compared to the reference drugs. Adherence to these guidelines streamline the regulatory approval process while also ensuring confidence with respect to the interchangeability of
Searchable Databases for Bio-Equivalence Guidance Read More »
